Cyclic nucleotides in the regulation of expression of differentiated functions in neuroblastoma cells.
Adenosine 3',5'-cyclic monophosphate (cAMP) may be one of the important factors in regulating the expression of many differentiated functions in neuroblastoma cells, but some of these functions can be induced by agents that do not increase the intracellular level of cAMP. An elevation of the intracellular level of guanosine 3',5'-cyclic monophosphate (cGMP) neither induced differentiation nor antagonized the effects of cAMP. Neuroblastoma cells increased the level of cAMP-binding proteins during differentiation, whereas glial cells and L-cells did not. This might have accounted in part for an increase in the intracellular level of cAMP even in the presence of high phosphodiesterase activity in neuroblastoma cells, since the protein-bound with the same proteins, but cAMP had about 10 times higher affinity than did cGMP. cAMP promoted the organization of microtubules and microfilaments necessary for the expression of differentiated phenotypes. The extension of neurites required the synthesis of new protein, but it did not need the synthesis of new RNA. cAMP induced differentiation in neuroblastoma cells by increasing the expression of some genetic information while suppressing the expression of others; e.g., the activities of neural enzymes increased, whereas the synthesis of histone and the phosphorylation of H1-histone markedly decreased in differentiated cells. A hypothesis was offered: An increase in cAMP phosphodiesterase activity as a result of mutation in the regulatory gene for phosphodiesterase in a single, or group of, dividing nerve cell(s) is the primary lesion that leads to malignancy. Based on the concept that selective cytocytoxic drugs should be used with agents that cause differentiation, a new therapeutic approach was suggested for the treatment of neuroblastoma. This involved administration of sodium butyrate followed by L-DOPA or prostaglandin E1 in the presence of cAMP phosphodiesterase inhibitor followed by the less immunosuppressive vincristine and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide.
D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D002087:Butyrates / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects; D000242:Cyclic AMP / Q000378:metabolism / Q000494:pharmacology; D006152:Cyclic GMP / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D008870:Microtubules / Q000187:drug effects; D008954:Models, Biological; D009374:Neoplasms, Experimental / Q000201:enzymology / Q000473:pathology / Q000628:therapy; D009447:Neuroblastoma / Q000201:enzymology / Q000473:pathology* / Q000628:therapy; D018377:Neurotransmitter Agents / Q000494:pharmacology; D009712:Nucleotides, Cyclic / Q000502:physiology*; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D011458:Prostaglandins E / Q000494:pharmacology; D011485:Protein Binding; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D002087:Butyrates; D018377:Neurotransmitter Agents; D009712:Nucleotides, Cyclic; D011458:Prostaglandins E; D000242:Cyclic AMP; D014446:Tyrosine 3-Monooxygenase; D010727:Phosphoric Diester Hydrolases; D000262:Adenylyl Cyclases; D006152:Cyclic GMP